- Quick emergence for neurological assessment1,3*,4*
- Supports return of cognitive function1,2*
Added characteristics of ULTIVA
- No difference in PK in obese patients (dose adjusted to IBW)1
- Can be used in patients with renal or hepatic impairment1
- Well-established hemodynamic profile1
Awake craniotomy case study
5'10'', 100 kg (220 lb)
BMI 31.6 kg/m2
Previous history of prolonged emergence
Previous history of postoperative nausea and vomiting
Medications: antidiabetic agent (oral), ACE inhibitor
This case study is for illustrative and educational purposes only. The dosing regimen is specific to this case study and other regimens may vary depending on patient and procedure. Any use of this product is subject to the judgment of the practitioner in each case. Please consult the full Prescribing Information in the use of this product.
ULTIVA should be used with caution in obese patients. Clearance of remifentanil generally correlates with total body weight and may vary in morbidly obese patients due to variation in physiology and pharmacodynamics.
- ULTIVA [package insert]. Rockford, IL: Mylan Institutional LLC; 2016.
- Guy J, Hindman BJ, Baker KZ, et al. Comparison of remifentanil and fentanyl in patients undergoing craniotomy for supratentorial space-occupying lesions. Anesthesiology. 1997;86(3):514-524.
- Gesztesi Z, Mootz BL, White PF. The use of a remifentanil infusion for hemodynamic control during intracranial surgery. Anesth Analg. 1999;89(5):1282-1287.
- Bilotta F, Caramia R, Paoloni FP, et al. Early postoperative cognitive recovery after remifentanil-propofol or sufentanil-propofol anaesthesia for supratentorial craniotomy: a randomized trial. Eur J Anaesthesiol. 2007;24(2):122-127.
- Samra SK, Dy EA, Welch KB, Lovely LK, Graziano GP. Remifentanil- and fentanyl-based anesthesia for intraoperative monitoring of somatosensory evoked potentials. Anesth Analg. 2001;92(6):1510-1515.